
    
      The study consists of two distinct treatment phases. The first is the 6-week open-label,
      treatment optimization phase during which subjects are titrated to an optimal daily dose of
      HLD200. Subjects are then randomized to receive either optimal HLD200 or matched placebo
      treatment for an additional week prior to final testing during a laboratory school day.
    
  